Heron Therapeutics (HRTX) Competitors $1.92 -0.01 (-0.52%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$1.88 -0.04 (-2.34%) As of 04/15/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock HRTX vs. CALT, AMPH, ADPT, ARDX, EVO, AUPH, BGM, OCUL, IOVA, and SNDXShould you be buying Heron Therapeutics stock or one of its competitors? The main competitors of Heron Therapeutics include Calliditas Therapeutics AB (publ) (CALT), Amphastar Pharmaceuticals (AMPH), Adaptive Biotechnologies (ADPT), Ardelyx (ARDX), Evotec (EVO), Aurinia Pharmaceuticals (AUPH), Qilian International Holding Group (BGM), Ocular Therapeutix (OCUL), Iovance Biotherapeutics (IOVA), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical products" industry. Heron Therapeutics vs. Calliditas Therapeutics AB (publ) Amphastar Pharmaceuticals Adaptive Biotechnologies Ardelyx Evotec Aurinia Pharmaceuticals Qilian International Holding Group Ocular Therapeutix Iovance Biotherapeutics Syndax Pharmaceuticals Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, community ranking, valuation, dividends and profitability. Is CALT or HRTX more profitable? Heron Therapeutics has a net margin of -20.31% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Heron Therapeutics' return on equity of 0.00% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96% Heron Therapeutics -20.31%N/A -12.72% Which has more risk & volatility, CALT or HRTX? Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500. Do insiders and institutionals hold more shares of CALT or HRTX? 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Comparatively, 5.8% of Heron Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community prefer CALT or HRTX? Heron Therapeutics received 641 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 68.87% of users gave Heron Therapeutics an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote. CompanyUnderperformOutperformCalliditas Therapeutics AB (publ)Outperform Votes2755.10% Underperform Votes2244.90% Heron TherapeuticsOutperform Votes66868.87% Underperform Votes30231.13% Which has preferable earnings and valuation, CALT or HRTX? Calliditas Therapeutics AB (publ) has higher revenue and earnings than Heron Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62Heron Therapeutics$144.29M2.03-$110.56M-$0.09-21.33 Does the media refer more to CALT or HRTX? In the previous week, Heron Therapeutics had 5 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 5 mentions for Heron Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Heron Therapeutics' average media sentiment score of 1.00 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Calliditas Therapeutics AB (publ) Neutral Heron Therapeutics Positive Do analysts prefer CALT or HRTX? Calliditas Therapeutics AB (publ) currently has a consensus target price of $39.25, indicating a potential downside of 1.88%. Heron Therapeutics has a consensus target price of $5.67, indicating a potential upside of 195.14%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Heron Therapeutics is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Heron Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryHeron Therapeutics beats Calliditas Therapeutics AB (publ) on 15 of the 18 factors compared between the two stocks. Remove Ads Get Heron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HRTX vs. The Competition Export to ExcelMetricHeron TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$294.00M$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-10.676.7921.7217.82Price / Sales2.03225.96376.8894.61Price / CashN/A65.6738.1534.64Price / Book-8.355.866.474.00Net Income-$110.56M$141.86M$3.20B$247.23M7 Day Performance2.13%4.50%2.86%1.45%1 Month Performance-17.24%-12.65%-8.55%-6.24%1 Year Performance-34.47%-11.06%10.58%0.60% Heron Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HRTXHeron Therapeutics3.4918 of 5 stars$1.92-0.5%$5.67+195.1%-34.9%$294.00M$144.29M-10.67300Positive NewsCALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180AMPHAmphastar Pharmaceuticals4.3008 of 5 stars$25.00-6.1%$43.50+74.0%-42.4%$1.19B$731.97M8.331,620News CoverageGap DownHigh Trading VolumeADPTAdaptive Biotechnologies3.2671 of 5 stars$7.71+3.2%$9.40+21.9%+166.0%$1.15B$178.96M-7.07790Positive NewsHigh Trading VolumeARDXArdelyx4.2047 of 5 stars$4.45-2.2%$10.61+138.5%-31.8%$1.06B$333.62M-27.8190Gap DownEVOEvotec1.4516 of 5 stars$2.97-2.9%$5.93+99.8%-53.5%$1.05B$777.05M0.004,200Upcoming EarningsGap UpAUPHAurinia Pharmaceuticals2.5745 of 5 stars$7.59-2.8%$11.50+51.5%+53.8%$1.04B$235.13M-50.60300News CoverageGap DownBGMQilian International Holding GroupN/A$10.62-0.9%N/AN/A$1.03B$25.10M0.00298Positive NewsOCULOcular Therapeutix3.4302 of 5 stars$6.30-0.9%$16.38+159.9%-3.5%$1.00B$63.72M-4.77230Gap DownIOVAIovance Biotherapeutics4.2358 of 5 stars$3.03+1.0%$20.25+568.3%-72.8%$993.47M$164.07M-2.03500Analyst ForecastNews CoverageHigh Trading VolumeSNDXSyndax Pharmaceuticals3.3478 of 5 stars$11.01-2.1%$36.20+228.8%-47.6%$947.34M$23.68M-3.03110Gap Down Remove Ads Related Companies and Tools Related Companies Calliditas Therapeutics AB (publ) Competitors Amphastar Pharmaceuticals Competitors Adaptive Biotechnologies Competitors Ardelyx Competitors Evotec Competitors Aurinia Pharmaceuticals Competitors Qilian International Holding Group Competitors Ocular Therapeutix Competitors Iovance Biotherapeutics Competitors Syndax Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HRTX) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy HRTX Stock Free HRTX Stock Alerts